One of the most important medical advances in recent years could become a reality. The Mosaic study, which meticulously analyzes the effectiveness of a vaccine in preventing HIV infection, is about to enter the trial phase.
Based on the combination of several virus proteins that are genetically added to a viral vector and that could be harmless to humans, this vaccine, if the results are as expected, could generate immunity against HIV and its different subtypes.
Carlos Cabrera, one of the researchers behind the vaccine, declared that the study is a historic achievement for humanity, stressing that it is the first clinical trial of an HIV vaccine in 10 years to be at stage 3.
Eight countries participate with Argentina, Peru, Mexico, Brazil and the United States from the American continent, and Spain, Italy and Poland from Europe. It is a study that aims to recruit 3800 volunteer participants around the world.
The researcher also explained that the operation of the immunizer is only effective preventively, that is, it only works for people who have not yet acquired HIV infection. However, it is still too early to calculate the percentage of effectiveness.
There have already been three other HIV vaccine candidates since the 1980s, and unfortunately, all of them have not reached 30 percent efficacy. So this one is promising, it would probably have that possibility of jumping that barrier, there is even talk that it could be 50 percent.